Lake Street Capital initiated coverage on shares of Biofrontera (NASDAQ:BFRA) in a report published on Wednesday, Marketbeat reports. The firm issued a buy rating and a $19.00 price target on the stock.
BFRA has been the topic of several other reports. ValuEngine lowered shares of Biofrontera from a hold rating to a sell rating in a research note on Monday, April 9th. Benchmark began coverage on shares of Biofrontera in a research report on Friday, March 9th. They set a buy rating and a $19.00 target price on the stock.
Biofrontera stock traded down $0.22 during mid-day trading on Wednesday, hitting $13.70. The company had a trading volume of 820 shares, compared to its average volume of 15,998. Biofrontera has a 1 year low of $11.25 and a 1 year high of $17.98. The company has a current ratio of 5.50, a quick ratio of 4.40 and a debt-to-equity ratio of 2.63.
Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin. Its products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin.
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.